BERLIN, Germany – Stealth BioTherapeutics, a front-runner in the world of mitochondrial medicine, is set to unveil its latest breakthroughs at the much-anticipated Targeting Mitochondria 2023 conference in Berlin this October.
Credit: World Mitochondria Society (WMS)
BERLIN, Germany – Stealth BioTherapeutics, a front-runner in the world of mitochondrial medicine, is set to unveil its latest breakthroughs at the much-anticipated Targeting Mitochondria 2023 conference in Berlin this October.
Dr. David A. Brown, Vice President of Mitochondrial Research at Stealth BioTherapeutics, is slated to give an enlightening talk titled, “Translational insights from targeting mitochondria in rare diseases.” His presentation promises to provide insights into Stealth’s progress in clinical programs, with updates on their advancements in addressing rare mitochondrial diseases across several Phase 2/3 clinical trials. Furthermore, he will elaborate on the emerging strategies to counteract mitochondrial dysfunction in various pathologies.
About Stealth BioTherapeutics:
Stealth BioTherapeutics is a clinical-stage biotechnology firm dedicated to the discovery, development, and commercialization of groundbreaking therapies targeting diseases caused by mitochondrial dysfunction. Dysfunctional mitochondria play a pivotal role in a myriad of rare genetic diseases as well as numerous prevalent age-related conditions. These typically affect organ systems with high energy needs, such as the eye, the neuromuscular system, the heart, and the brain.
About World Mitochondria Society:
The World Mitochondria Society is an international non-profit organization dedicated to promoting research and education about mitochondria in health and disease. It aims to bridge the gap between scientists and healthcare professionals globally, disseminating knowledge and fostering collaborations to advance the understanding of mitochondrial function and dysfunction.
